A decade ago, most people had never heard of vitamin K2. Today it's a standard ingredient on bone-health and heart-health supplement labels, sold alongside calcium and vitamin D as if it always belonged there. That shift — from nutritional afterthought to mainstream supplement staple — didn't happen by accident, and tracing how it happened explains more about this market's future than the growth percentage alone.

The Market Today

The global vitamin K2 market was valued at USD 320.0 million in 2025 and is projected to reach USD 1,038.5 million by 2033, growing at a CAGR of 16.6% from 2026 to 2033 — a growth rate that puts it well ahead of the broader dietary supplements category, which typically grows in the high single digits.

Asia Pacific currently holds the largest regional share, at 36.7% in 2025, while within the product itself, MK-4 (menaquinone-4) dominates with an 88.5% revenue share. By dosage form, capsules and tablets lead at 41.8%, and synthetic sources account for 67.8% of supply, meaningfully ahead of naturally fermented K2 sources.

Why MK-4 Still Dominates Despite MK-7's Better Reputation

Anyone who's researched vitamin K2 supplements has likely encountered the MK-4 versus MK-7 debate. MK-7 (menaquinone-7) is frequently marketed as superior due to its longer half-life in the bloodstream, meaning it stays active in the body longer per dose than MK-4. Given that reputation, MK-4's overwhelming 88.5% share might seem counterintuitive — until you account for cost and regulatory history rather than bioavailability alone.

MK-4 has a longer track record of use, particularly in Japan, where it has been used in the management of bone-related conditions for decades under regulatory frameworks that predate MK-7's rise in the wider supplement market. That regulatory head start, combined with lower synthetic production costs, is why MK-4 remains the dominant product form even as MK-7 captures a disproportionate share of the research attention and premium-brand marketing narrative. The gap between MK-4's revenue dominance and MK-7's brand momentum is arguably the single most important dynamic in this market right now — and it's rarely discussed directly.

Download a free sample report or claim your copy of this full market intelligence report

The U.S. Growth Story Nobody's Tracking Closely Enough

The U.S. vitamin K2 market generated USD 78.5 million in 2025 and is projected to reach USD 247.8 million by 2033, a CAGR of 16.2% — nearly matching the global growth rate despite the U.S. currently holding a smaller share of the world market than Asia Pacific. Within the U.S. specifically, MK-4 remains the largest product segment by current revenue, but MK-7 is the fastest-growing product type in the American market.

This divergence between "largest" and "fastest-growing" within the same country is a pattern worth watching closely, because it suggests the U.S. market is in the middle of exactly the kind of product-mix transition that already played out with omega-3 supplements: an established, lower-cost format holding current revenue share while a premium-positioned alternative captures new customer growth. If that pattern holds, MK-7 could realistically overtake MK-4's revenue share within the U.S. market well before it does so globally.

The Synthetic-Versus-Natural Question Consumers Are Starting to Ask

Synthetic vitamin K2 accounts for 67.8% of the market, a share driven primarily by cost and manufacturing scalability — synthetic production allows for consistent dosing and lower per-unit costs compared to fermentation-derived natural K2. But as "clean label" and naturally sourced supplement trends continue reshaping consumer purchasing behavior across the broader nutraceutical industry, natural K2 sourced from fermented foods (traditionally derived from natto, a fermented soybean product with deep roots in Japanese cuisine) represents a segment likely to gain share disproportionately to its current size, even if it never approaches synthetic's overall dominance.

Brands positioning around "naturally fermented" or "food-derived" K2 sourcing are, in effect, betting on the same consumer shift that already reshaped markets for probiotics and omega-3s — where natural or minimally processed positioning commands both a price premium and stronger customer loyalty, even without clear evidence of superior efficacy over well-formulated synthetic alternatives.

Looking for more in-depth data focusing on specific segments or regions? Get this report customized with inclusion of custom data sets to suit your exact business needs

Where the Next Wave of Demand Is Actually Coming From

Aging population trends and rising osteoporosis and cardiovascular disease prevalence are the drivers cited in virtually every summary of this market, and they're accurate — but they describe demand growth in the existing bone-and-heart-health use case. The more interesting emerging driver is vitamin K2's expanding role in functional foods and fortified products, moving the ingredient beyond the supplement aisle entirely and into dairy alternatives, fortified beverages, and infant nutrition formulations in specific markets.

This shift matters because functional-food fortification typically scales distribution far faster than standalone supplement sales, since it rides on existing food product distribution and doesn't require consumers to make an active decision to seek out and purchase a dedicated supplement. If vitamin K2 fortification gains meaningful traction in mainstream packaged food categories over the next several years, it could meaningfully accelerate the market's growth rate beyond even the current 16.6% CAGR projection — a possibility that pure supplement-market analysis tends to overlook.

Reading the Category's Next Decade

No single breakthrough explains vitamin K2's climb from obscurity to a market on track for USD 1,038.5 million by 2033 — it was built in layers, each one still active today. Japan's decades of clinical MK-4 use laid the foundation. Western marketing did the work of premiumizing MK-7 on top of it. And functional food fortification is only now starting to add a third layer that could end up larger than the first two combined, simply because it doesn't ask consumers to buy a supplement at all. Whichever of these three layers accelerates fastest in a given country over the next few years will tell you far more about that market's trajectory than its blended national growth rate ever could.